The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients

Zhonghua nei ke za zhi

Volumn 54, Issue 8, 2015, Pages 699-704

  Rao, Huiying ^a   Yang, Ruifeng ^a   Shang, Jia ^a   Xu, Xiaoyuan ^a   Chen, Xinyue ^a   Dou, Xiaoguang ^a   Feng, Yinong ^a   Gao, Zhiliang ^a   Xie, Qing ^a   Li, Jun ^a   You, Hong ^a   Chen, Guofeng ^a   Niu, Junqi ^a   Gong, Guozhong ^a   Hou, Jinlin ^a   Chen, Hong ^a   Zhang, Dazhi ^a   Wei, Lai ^b  

^a Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases ^*

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84954605997     PISSN: 05781426     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)